REFERENCES
1. Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023;79:516-37.
2. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-63.
3. Lin J, Zhang H, Yu H, et al. Epidemiological characteristics of primary liver cancer in mainland china from 2003 to 2020: a representative multicenter study. Front Oncol. 2022;12:906778.
4. GBD Results. Institute for Health Metrics and Evaluation. Available from: https://vizhub.healthdata.org/gbd-results. [Last accessed on 15 Jan 2025].
5. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604.
7. Rumgay H, Arnold M, Ferlay J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598-606.
8. Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020;147:317-30.
9. Arnold M, Abnet CC, Neale RE, et al. Global burden of 5 major types of gastrointestinal cancer. Gastroenterology. 2020;159:335-49.e15.
10. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan childhood hepatoma study group. N Engl J Med. 1997;336:1855-9.
11. Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis. Annu Rev Med. 2016;67:103-17.
12. Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 2020;126:2666-78.
13. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66:115-32.
14. Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400:1345-62.
15. Ahn JC, Lee YT, Agopian VG, et al. Hepatocellular carcinoma surveillance: current practice and future directions. Hepatoma Res. 2022;8:10.
16. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73 Suppl 1:4-13.
18. Li Z, Chen J, Tang Y, Qin D, Tang Z. MASLD: an emerging factor in the pathophysiology and clinical management of ICC. Hepatoma Res. 2024;10:41.
19. Turati F, Bertuccio P, Negri E, La Vecchia C. Epidemiology of cholangiocarcinoma. Hepatoma Res. 2022;8:19.
20. Yu Q, Lei Z, Ma W, et al. Postoperative prognosis of non-alcoholic fatty liver disease-associated intrahepatic cholangiocarcinoma: a multi-center propensity score matching analysis. J Gastrointest Surg. 2023;27:2403-13.
21. World Health Organization. Hepatitis B. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b. [Last accessed on 15 Jan 2025].
22. World Health Organization. Hepatitis C. Available from: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c. [Last accessed on 15 Jan 2025].
23. Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019;70:151-71.
24. Tian Z, Xu C, Yang P, et al. Molecular pathogenesis: connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma. Front Immunol. 2022;13:984728.
25. De Mitri MS, Poussin K, Baccarini P, et al. HCV-associated liver cancer without cirrhosis. Lancet. 1995;345:413-5.
26. World Health Organization (WHO). Available from: https://www.who.int/zh. [Last accessed on 15 Jan 2025].
27. International Diabetes Federation. 1 in 10 people are living with diabetes. Available from: https://idf.org/. [Last accessed on 15 Jan 2025].
28. Lazarus JV, Newsome PN, Francque SM, Kanwal F, Terrault NA, Rinella ME. Reply: a multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2024;79:E93-4.
29. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223-38.
30. Wegermann K, Diehl AM, Moylan CA. Challenges and barriers in hepatocellular carcinoma (HCC) surveillance for patients with non-alcoholic fatty liver disease (NAFLD). Hepatoma Res. 2023;9:11.
31. Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723-30.
32. Piciotti R, Longo M, Agresta A, et al. Old-fashioned and newly discovered biomarkers: the future of NAFLD-related HCC screening and monitoring. Hepatoma Res. 2022;8:37.
33. Desai A, Sandhu S, Lai JP, Sandhu DS. Hepatocellular carcinoma in non-cirrhotic liver: a comprehensive review. World J Hepatol. 2019;11:1-18.
34. Park EJ, Lee JH, Yu GY, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell. 2010;140:197-208.
35. Yang JD, Mohamed HA, Cvinar JL, Gores GJ, Roberts LR, Kim WR. Diabetes mellitus heightens the risk of hepatocellular carcinoma except in patients with hepatitis C cirrhosis. Am J Gastroenterol. 2016;111:1573-80.
36. Jinjuvadia R, Patel S, Liangpunsakul S. The association between metabolic syndrome and hepatocellular carcinoma: systemic review and meta-analysis. J Clin Gastroenterol. 2014;48:172-7.
37. Hydes TJ, Cuthbertson DJ, Graef S, et al. The impact of diabetes and glucose-lowering therapies on hepatocellular carcinoma incidence and overall survival. Clin Ther. 2022;44:257-68.
38. Lee JY, Jang SY, Nam CM, Kang ES. Incident hepatocellular carcinoma risk in patients treated with a sulfonylurea: a nationwide, nested, case-control study. Sci Rep. 2019;9:8532.
39. Zhang X, Goh GB, Chan WK, et al. Unhealthy lifestyle habits and physical inactivity among Asian patients with non-alcoholic fatty liver disease. Liver Int. 2020;40:2719-31.
40. Singh S, Singh PP, Singh AG, Murad MH, Sanchez W. Statins are associated with a reduced risk of hepatocellular cancer: a systematic review and meta-analysis. Gastroenterology. 2013;144:323-32.
41. Pradelli D, Soranna D, Scotti L, et al. Statins and primary liver cancer: a meta-analysis of observational studies. Eur J Cancer Prev. 2013;22:229-34.
42. Gregory SN, Perati SR, Brown ZJ. Alteration in immune function in patients with fatty liver disease. Hepatoma Res. 2022;8:31.
43. Llovet JM, Willoughby CE, Singal AG, et al. Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment. Nat Rev Gastroenterol Hepatol. 2023;20:487-503.
44. Bagnardi V, Rota M, Botteri E, et al. Alcohol consumption and site-specific cancer risk: a comprehensive dose-response meta-analysis. Br J Cancer. 2015;112:580-93.
45. World Health Organization. Global status report on alcohol and health 2018. Available from: https://www.who.int/publications/i/item/9789241565639. [Last accessed on 15 Jan 2025].
46. Huang DQ, Mathurin P, Cortez-Pinto H, Loomba R. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20:37-49.
47. Chidambaranathan-reghupaty S, Fisher PB, Sarkar D. Hepatocellular carcinoma (HCC): epidemiology, etiology and molecular classification. Adv Cancer Res. 2021;149:1-61.
48. Liu SY, Tsai IT, Hsu YC. Alcohol-related liver disease: basic mechanisms and clinical perspectives. Int J Mol Sci. 2021;22:5170.
49. Tsai MC, Yang SS, Lin CC, et al. Association of heavy alcohol intake and ALDH2 rs671 polymorphism with hepatocellular carcinoma and mortality in patients with hepatitis B virus-related cirrhosis. JAMA Netw Open. 2022;5:e2223511.
50. Su D. Drinking water and liver cell cancer: an epidemiologic approach to the etiology of this disease in China. Chin Med J. 1979;92:748-56. Available from: https://pubmed.ncbi.nlm.nih.gov/116818/. [Last accessed on 15 Jan 2025].
51. Jin J, Kouznetsova VL, Kesari S, Tsigelny IF. Synergism in actions of HBV with aflatoxin in cancer development. Toxicology. 2023;499:153652.
52. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect. 2010;118:818-24.
53. Sun J, Althoff KN, Jing Y, et al; North American AIDS Cohort Collaboration on Research and Design of IeDEA. Trends in hepatocellular carcinoma incidence and risk among persons with HIV in the US and Canada, 1996-2015. JAMA Netw Open. 2021;4:e2037512.
54. Yin J, Xie J, Liu S, et al. Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma. Am J Gastroenterol. 2011;106:81-92.
55. Yin J, Xie J, Zhang H, et al. Significant association of different preS mutations with hepatitis B-related cirrhosis or hepatocellular carcinoma. J Gastroenterol. 2010;45:1063-71.
56. Liu S, Xie J, Yin J, et al. A matched case-control study of hepatitis B virus mutations in the preS and core promoter regions associated independently with hepatocellular carcinoma. J Med Virol. 2011;83:45-53.
57. Xie JX, Zhao J, Yin JH, et al. Association of novel mutations and haplotypes in the preS region of hepatitis B virus with hepatocellular carcinoma. Front Med China. 2010;4:419-29.
58. Liu S, Zhang H, Gu C, et al. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst. 2009;101:1066-82.
59. Li Z, Xie Z, Ni H, et al. Mother-to-child transmission of hepatitis B virus: evolution of hepatocellular carcinoma-related viral mutations in the post-immunization era. J Clin Virol. 2014;61:47-54.
60. Yin J, Wang J, Pu R, et al. Hepatitis B virus combo mutations improve the prediction and active prophylaxis of hepatocellular carcinoma: a clinic-based cohort study. Cancer Prev Res. 2015;8:978-88.
61. Yin J, Chen X, Li N, et al. Compartmentalized evolution of hepatitis B virus contributes differently to the prognosis of hepatocellular carcinoma. Carcinogenesis. 2021;42:461-70.
62. Chen X, Zhang M, Li N, et al. Nucleotide variants in hepatitis B virus preS region predict the recurrence of hepatocellular carcinoma. Aging. 2021;13:22256-75.
63. Pu R, Liu W, Zhou X, et al. The effects and underlying mechanisms of hepatitis B virus X gene mutants on the development of hepatocellular carcinoma. Front Oncol. 2022;12:836517.
64. Liu W, Cai S, Pu R, et al. HBV preS mutations promote hepatocarcinogenesis by inducing endoplasmic reticulum stress and upregulating inflammatory signaling. Cancers. 2022;14:3274.
65. Jiang DK, Sun J, Cao G, et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet. 2013;45:72-5.
66. Shen T, Ni T, Chen J, et al. An enhancer variant at 16q22.1 predisposes to hepatocellular carcinoma via regulating PRMT7 expression. Nat Commun. 2022;13:1232.
67. Zhang Q, Yin J, Zhang Y, et al. HLA-DP polymorphisms affect the outcomes of chronic hepatitis B virus infections, possibly through interacting with viral mutations. J Virol. 2013;87:12176-86.
68. Song J, Yang F, Wang S, et al. Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: a meta-analysis. J Viral Hepat. 2019;26:397-406.
69. Ji X, Zhang Q, Li B, et al. Impacts of human leukocyte antigen DQ genetic polymorphisms and their interactions with hepatitis B virus mutations on the risks of viral persistence, liver cirrhosis, and hepatocellular carcinoma. Infect Genet Evol. 2014;28:201-9.
70. He Y, Zhang H, Yin J, et al. IkappaBalpha gene promoter polymorphisms are associated with hepatocarcinogenesis in patients infected with hepatitis B virus genotype C. Carcinogenesis. 2009;30:1916-22.
71. Zhang Q, Ji XW, Hou XM, et al. Effect of functional nuclear factor-kappaB genetic polymorphisms on hepatitis B virus persistence and their interactions with viral mutations on the risk of hepatocellular carcinoma. Ann Oncol. 2014;25:2413-9.
72. Xie J, Zhang Y, Zhang Q, et al. Interaction of signal transducer and activator of transcription 3 polymorphisms with hepatitis B virus mutations in hepatocellular carcinoma. Hepatology. 2013;57:2369-77.
73. Liu W, Wu J, Yang F, et al. Genetic polymorphisms predisposing the interleukin 6-induced APOBEC3B-UNG imbalance increase HCC risk via promoting the generation of APOBEC-signature HBV mutations. Clin Cancer Res. 2019;25:5525-36.
74. Liu W, Ji H, Zhao J, et al. Transcriptional repression and apoptosis influence the effect of APOBEC3A/3B functional polymorphisms on biliary tract cancer risk. Int J Cancer. 2022;150:1825-37.
75. Tan X, Zheng S, Liu W, et al. Effect of APOBEC3A functional polymorphism on renal cell carcinoma is influenced by tumor necrosis factor-α and transcriptional repressor ETS1. Am J Cancer Res. 2021;11:4347-63. Available from: https://www.worldobesity.org/resources/resource-library/world-obesity-atlas-2023. [Last accessed on 15 Jan 2025].
76. Xian L, Zhao P, Chen X, et al. Heterogeneity, inherent and acquired drug resistance in patient-derived organoid models of primary liver cancer. Cell Oncol. 2022;45:1019-36.
77. Chang W, Gao X, Han Y, et al. Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. Gut. 2014;63:1457-67.
78. Cancer Genome Atlas Research Network. Electronic address: [email protected]; Cancer Genome Atlas Research Network. Comprehensive and integrative genomic characterization of hepatocellular carcinoma. Cell. 2017;169:1327-41.e23.
79. Désert R, Rohart F, Canal F, et al. Human hepatocellular carcinomas with a periportal phenotype have the lowest potential for early recurrence after curative resection. Hepatology. 2017;66:1502-18.
80. Tan JH, Zhou WY, Zhou L, Cao RC, Zhang GW. Viral hepatitis B and C infections increase the risks of intrahepatic and extrahepatic cholangiocarcinoma: evidence from a systematic review and meta-analysis. Turk J Gastroenterol. 2020;31:246-56.
81. Zhang H, Zhu B, Zhang H, Liang J, Zeng W. HBV infection status and the risk of cholangiocarcinoma in Asia: a meta-analysis. Biomed Res Int. 2016;2016:3417976.
82. Li M, Li J, Li P, et al. Hepatitis B virus infection increases the risk of cholangiocarcinoma: a meta-analysis and systematic review. J Gastroenterol Hepatol. 2012;27:1561-8.
83. Palmer WC, Patel T. Are common factors involved in the pathogenesis of primary liver cancers? J Hepatol. 2012;57:69-76.
84. Zhou Y, Zhao Y, Li B, et al. Hepatitis viruses infection and risk of intrahepatic cholangiocarcinoma: evidence from a meta-analysis. BMC Cancer. 2012;12:289.
85. Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma. BMC Cancer. 2019;19:185.
86. Wang C, Yang W, Yan HX, et al. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology. 2012;55:108-20.
87. Gao C, Zhou G, Shi J, et al. The A-to-I editing of KPC1 promotes intrahepatic cholangiocarcinoma by attenuating proteasomal processing of NF-κB1 p105 to p50. J Exp Clin Cancer Res. 2022;41:338.
88. Beal EW, Gorji L, Volney J, Sova L, Mcalearney AS, Tsung A. Barriers to surveillance for hepatocellular cancer among patients with chronic liver disease -providers’ perspectives. Hepatoma Res. 2023;9:45.
89. Lee YT, Fujiwara N, Yang JD, Hoshida Y. Risk stratification and early detection biomarkers for precision HCC screening. Hepatology. 2023;78:319-62.
90. Mózes FE, Lee JA, Selvaraj EA, et al; LITMUS Investigators. Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. Gut. 2022;71:1006-19.
91. Hydes TJ, Cuthbertson DJ, Palmer DH, et al. Ultrasonography in surveillance for hepatocellular carcinoma in patients with non-alcoholic fatty liver disease. Hepatoma Res. 2023;9:12.
92. Singal AG, Llovet JM, Yarchoan M, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922-65.
93. Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 2017;11:317-70.
94. Vogel A, Cervantes A, Chau I, et al; ESMO Guidelines Committee. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv238-55.
95. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182-236.
96. Hasegawa K, Takemura N, Yamashita T, et al; committee for Revision of the Clinical Practice Guidelines for Hepatocellular Carcinoma, Tokyo, Japan. Clinical Practice Guidelines for hepatocellular carcinoma: the Japan society of hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383-90.
97. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol. 2006;101:513-23.
98. Kim SY, An J, Lim YS, et al. MRI with liver-specific contrast for surveillance of patients with cirrhosis at high risk of hepatocellular carcinoma. JAMA Oncol. 2017;3:456-63.
99. Park J, Lee JM, Kim TH, Yoon JH. Imaging diagnosis of hepatocellular carcinoma: future directions with special emphasis on hepatobiliary magnetic resonance imaging and contrast-enhanced ultrasound. Clin Mol Hepatol. 2022;28:362-79.
100. Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: a meta-analysis. Gastroenterology. 2018;154:1706-18.e1.
101. Singal A, Volk ML, Waljee A, et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther. 2009;30:37-47.
102. Yu NC, Chaudhari V, Raman SS, et al. CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis. Clin Gastroenterol Hepatol. 2011;9:161-7.
103. Samoylova ML, Mehta N, Roberts JP, Yao FY. Predictors of ultrasound failure to detect hepatocellular carcinoma. Liver Transpl. 2018;24:1171-7.
104. Goh MJ, Sinn DH, Kim JM, et al. Clinical practice guideline and real-life practice in hepatocellular carcinoma: a Korean perspective. Clin Mol Hepatol. 2023;29:197-205.
105. Yip TC, Lee HW, Chan WK, Wong GL, Wong VW. Asian perspective on NAFLD-associated HCC. J Hepatol. 2022;76:726-34.
106. Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60:1268-89.
107. Cai Y, Cheng N, Ye H, Li F, Song P, Tang W. The current management of cholangiocarcinoma: a comparison of current guidelines. Biosci Trends. 2016;10:92-102.
108. Cabibbo G, Daniele B, Borzio M, et al. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice treatment guidelines of the Italian association for the study of the liver (AISF), Italian association of medical oncology (AIOM), Italian ASSOCIATION OF HEPATO-BILIO-PANCREATIC SURGery (AICEP), Italian association of hospital gastroenterologists (AIGO), Italian association of radiology and clinical oncology (AIRO), Italian society of pathological anatomy and diagnostic cytology (SIAPeC-IAP), Italian society of surgery (SIC), Italian society of gastroenterology (SIGE), Italian society of medical and interventional radiology (SIRM), Italian organ transplant society (SITO), and association of patients with hepatitis and liver disease (EpaC) - part I - surgical treatments. Dig Liver Dis. 2024;56:223-34.
109. Ricke J, Seidensticker M, Mohnike K. Noninvasive diagnosis of hepatocellular carcinoma in cirrhotic liver: current guidelines and future prospects for radiological imaging. Liver Cancer. 2012;1:51-8.
110. Harris PS, Hansen RM, Gray ME, Massoud OI, McGuire BM, Shoreibah MG. Hepatocellular carcinoma surveillance: an evidence-based approach. World J Gastroenterol. 2019;25:1550-9.
111. Singal AG, El-Serag HB. Rational HCC screening approaches for patients with NAFLD. J Hepatol. 2022;76:195-201.
112. Rao SX, Wang J, Wang J, et al. Chinese consensus on the clinical application of hepatobiliary magnetic resonance imaging contrast agent: Gadoxetic acid disodium. J Dig Dis. 2019;20:54-61.
113. Mao Y, Wang J, Zhu Y, et al. Gd-EOB-DTPA-enhanced MRI radiomic features for predicting histological grade of hepatocellular carcinoma. Hepatobiliary Surg Nutr. 2022;11:13-24.
114. Xie D, Shi J, Zhou J, Fan J, Gao Q. Clinical practice guidelines and real-life practice in hepatocellular carcinoma: a Chinese perspective. Clin Mol Hepatol. 2023;29:206-16.
116. Gisder DM, Tannapfel A, Tischoff I. Histopathology of hepatocellular carcinoma - when and what. Hepatoma Res. 2022;8:4.
117. Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97-104.
118. Xing H, Zheng YJ, Han J, et al. Protein induced by vitamin K absence or antagonist-II versus alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: a systematic review with meta-analysis. Hepatobiliary Pancreat Dis Int. 2018;17:487-95.
119. Tayob N, Kanwal F, Alsarraj A, Hernaez R, El-Serag HB. The performance of AFP, AFP-3, DCP as Biomarkers for detection of hepatocellular carcinoma (HCC): a phase 3 biomarker study in the United States. Clin Gastroenterol Hepatol. 2023;21:415-23.e4.
120. Zhang X, Xu Y, Qian Z, et al. circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma. Cell Death Dis. 2018;9:1091.
121. Cai J, Chen L, Zhang Z, et al. Genome-wide mapping of 5-hydroxymethylcytosines in circulating cell-free DNA as a non-invasive approach for early detection of hepatocellular carcinoma. Gut. 2019;68:2195-205.
122. Kim AK, Hamilton JP, Lin SY, et al. Urine DNA biomarkers for hepatocellular carcinoma screening. Br J Cancer. 2022;126:1432-8.
123. Corte A, Di Gaeta E, Steidler S, De Cobelli F. Radiological imaging and non-surgical local treatments for cholangiocarcinoma. Hepatoma Res. 2022;8:5.
124. Hamaoka M, Kozaka K, Matsui O, et al. Early detection of intrahepatic cholangiocarcinoma. Jpn J Radiol. 2019;37:669-84.
125. Bragazzi MC, Venere R, Ribichini E, Covotta F, Cardinale V, Alvaro D. Intrahepatic cholangiocarcinoma: evolving strategies in management and treatment. Dig Liver Dis. 2024;56:383-93.
126. Krenzien F, Nevermann N, Krombholz A, et al. Treatment of intrahepatic cholangiocarcinoma-a multidisciplinary approach. Cancers. 2022;14:362.
127. Muñoz-martínez S, Rimola J, Londoño MC, Cárdenas A, Forner A. Cholangiocarcinoma: early detection and screening in high-risk population. Hepatoma Res. 2022;8:30.
128. Choi SH, Lee SS, Kim SY, et al. Intrahepatic cholangiocarcinoma in patients with cirrhosis: differentiation from hepatocellular carcinoma by using gadoxetic acid-enhanced MR imaging and dynamic CT. Radiology. 2017;282:771-81.
129. Lu T, Ma J, Zou J, Jiang C, Li Y, Han J. CT-based intratumoral and peritumoral deep transfer learning features prediction of lymph node metastasis in non-small cell lung cancer. J Xray Sci Technol. 2024;32:597-609.
130. Wang H, Zhang J, Li Y, et al. Deep-learning features based on F18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) to predict preoperative colorectal cancer lymph node metastasis. Clin Radiol. 2024;79:e1152-8.
131. Zhu Y, Fu C, Du J, Jin Y, Du S, Zhao F. Prediction of cervical cancer lymph node metastasis via a multimodal transfer learning approach. Br J Hosp Med. 2024;85:1-14.
132. Zhang B, Jin B, Wu X, et al. Investigation of transcriptional and immunological disparities among patient groups with varied prognostic risk factors in cholangiocarcinoma. Cancer Med. 2024;13:e70135.
133. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-38.
134. Wu Y, Wakil A, Salomon F, Pyrsopoulos N. Issue on combined locoregional and systemic treatment for hepatocellular carcinoma. Hepatoma Res. 2023;9:6.
135. Roayaie S, Obeidat K, Sposito C, et al. Resection of hepatocellular cancer ≤ 2 cm: results from two Western centers. Hepatology. 2013;57:1426-35.
136. Zhou J, Sun H, Wang Z, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). Liver Cancer. 2020;9:682-720.
137. Tabrizian P, Jibara G, Shrager B, Schwartz M, Roayaie S. Recurrence of hepatocellular cancer after resection: patterns, treatments, and prognosis. Ann Surg. 2015;261:947-55.
138. Koh YX, Tan HJ, Liew YX, et al. Liver resection for nonalcoholic fatty liver disease-associated hepatocellular carcinoma. J Am Coll Surg. 2019;229:467-78.e1.
139. Molinari M, Kaltenmeier C, Samra PB, et al. Hepatic resection for hepatocellular carcinoma in nonalcoholic fatty liver disease: a systematic review and meta-analysis of 7226 patients. Ann Surg Open. 2021;2:e065.
140. Kung JWC, Ng KKC. Role of locoregional therapies in the management of patients with hepatocellular carcinoma. Hepatoma Res. 2022;8:17.
141. Cassese G, Han H, Lee B, Lee HW, Cho JY, Troisi R. The role of minimally invasive surgery in the treatment of HCC. Hepatoma Res. 2022;8:26.
142. Squires MH, Cloyd JM, Dillhoff M, Schmidt C, Pawlik TM. Challenges of surgical management of intrahepatic cholangiocarcinoma. Expert Rev Gastroenterol Hepatol. 2018;12:671-81.
143. Dopazo C, Charco R. Liver transplantation for perihilar cholangiocarcinoma. Do we need to move forward? Hepatoma Res. 2023;9:10.
144. Qin D, Chen J, Tang Y, et al. Evaluation of the outcomes of staging laparoscopy in intrahepatic cholangiocarcinoma patients undergoing surgical resection: a multicenter retrospective study in China. Hepatoma Res. 2024;10:40.
145. Aliseda D, Sapisochin G, Martí-Cruchaga P, et al. Association of laparoscopic surgery with improved perioperative and survival outcomes in patients with resectable intrahepatic cholangiocarcinoma: a systematic review and meta-analysis from propensity-score matched studies. Ann Surg Oncol. 2023;30:4888-901.
146. Umeda Y, Takagi K, Matsuda T, et al. Clinical implications and optimal extent of lymphadenectomy for intrahepatic cholangiocarcinoma: a multicenter analysis of the therapeutic index. Ann Gastroenterol Surg. 2023;7:512-22.
147. Sha M, Cao J, Qin CL, et al. Impact of lymph node dissection for patients with clinically node-negative intrahepatic cholangiocarcinoma: a multicenter cohort study. World J Oncol. 2024;15:579-91.
148. Ishii T, Iwaki K, Nakakura A, Yoh T, Uchida Y, Hatano E. Is routine lymph node dissection recommended for liver resection of intrahepatic cholangiocarcinoma? HPB. 2024;26:731-40.
149. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-9.
150. Tabrizian P, Holzner ML, Mehta N, et al. Ten-year outcomes of liver transplant and downstaging for hepatocellular carcinoma. JAMA Surg. 2022;157:779-88.
151. Franssen B, Jibara G, Tabrizian P, Schwartz ME, Roayaie S. Actual 10-year survival following hepatectomy for hepatocellular carcinoma. HPB. 2014;16:830-5.
152. Mok JHM, Ma KW, Chok KSH. Experience of living donor liver transplantation for hepatocellular carcinoma in the University of Hong Kong Hospital. Hepatoma Res. 2022;8:6.
153. Cucchetti A, Zhong J, Berhane S, et al. The chances of hepatic resection curing hepatocellular carcinoma. J Hepatol. 2020;72:711-7.
154. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999;30:1434-40.
155. Novoa F, Ardiles V, Pekolj J, Mattera J, de Santibañes M. Liver transplantation for intrahepatic cholangiocarcinoma: a narrative review of the latest advances. Hepatoma Res. 2023;9:33.
156. Sturdevant M, Zidan A, Broering D. Robotic donor hepatectomy: a niche advancement or the way forward? Hepatoma Res. 2022;8:1.
157. Kulik L, Heimbach JK, Zaiem F, et al. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis. Hepatology. 2018;67:381-400.
158. Yao FY, Mehta N, Flemming J, et al. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria. Hepatology. 2015;61:1968-77.
159. Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18:293-313.
160. Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg. 2017;104:1775-84.
161. Xia Y, Li J, Liu G, et al. Long-term effects of repeat hepatectomy vs percutaneous radiofrequency ablation among patients with recurrent hepatocellular carcinoma: a randomized clinical trial. JAMA Oncol. 2020;6:255-63.
162. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer. 2012;48:1977-87.
163. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018;67:358-80.
164. Renzulli M, Gentilini M, Marasco G, et al. The duration of the conventional chemoembolization for hepatocellular carcinoma: factors affecting the procedural time. Hepatoma Res. 2022;8:27.
165. Woerner AJ, Johnson GE. Advances in Y-90 radioembolization for the treatment of hepatocellular carcinoma. Hepatoma Res. 2022;8:2.
166. Zhang Y, Li Y, Ji H, Zhao X, Lu H. Transarterial Y90 radioembolization versus chemoembolization for patients with hepatocellular carcinoma: a meta-analysis. Biosci Trends. 2015;9:289-98.
167. An T, Wehrenberg-Klee E. Trans-arterial chemoembolization and radioembolization for treatment of intrahepatic cholangiocarcinoma. Hepatoma Res. 2023;9:43.
168. Owen M, Makary MS, Beal EW. Locoregional therapy for intrahepatic cholangiocarcinoma. Cancers. 2023;15:2384.
169. Melchiorre F, Patella F, Pescatori L, et al. DEB-TACE: a standard review. Future Oncol. 2018;14:2969-84.
170. Cho Y, Choi JW, Kwon H, et al; Research Committee of the Korean Liver Cancer Association. Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean liver cancer association. Clin Mol Hepatol. 2023;29:521-41
171. Gu Y, Zhang T, Zuo M, et al. Hepatic artery infusion chemotherapy (HAIC) combined with apatinib and camrelizumab for hepatocellular carcinoma (HCC) in BCLC stage c: a prospective, single-arm, phase II trial (TRIPLET study). JCO. 2022;40:4106.
172. Liu D, Mu H, Liu C, et al. Hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and bevacizumab biosimilar (IBI305) for initial unresectable hepatocellular carcinoma (HCC): a prospective, single-arm phase II trial. JCO. 2022;40:4073.
173. Ke Q, Lin N, Deng M, Wang L, Zeng Y, Liu J. The effect of adjuvant therapy for patients with intrahepatic cholangiocarcinoma after surgical resection: a systematic review and meta-analysis. PLoS One. 2020;15:e0229292.
174. Sheka AC, Altman A, Marmor S, et al. Failure to administer multimodality therapy leads to sub-optimal outcomes for patients with node-positive biliary tract cancers in the United States. Surg Oncol. 2020;34:298-303.
175. Vogel A, Martinelli E; ESMO Guidelines Committee. Electronic address: [email protected]; ESMO Guidelines Committee. Updated treatment recommendations for hepatocellular carcinoma (HCC) from the ESMO clinical practice guidelines. Ann Oncol. 2021;32:801-5
176. Bruix J, Chan SL, Galle PR, Rimassa L, Sangro B. Systemic treatment of hepatocellular carcinoma: an EASL position paper. J Hepatol. 2021;75:960-74.
177. Su GL, Altayar O, O'Shea R, et al. AGA clinical practice guideline on systemic therapy for hepatocellular carcinoma. Gastroenterology. 2022;162:920-34.
178. Fu C, Chen H, Chen Y, Liu W, Cao G. Transarterial intervention therapy combined with systemic therapy for HCC: a review of recent five-year articles. Hepatoma Res. 2024;10:42.
179. Zhou H, Song T. Conversion therapy and maintenance therapy for primary hepatocellular carcinoma. Biosci Trends. 2021;15:155-60.
180. Cheng H, Sun G, Chen H, et al. Trends in the treatment of advanced hepatocellular carcinoma: immune checkpoint blockade immunotherapy and related combination therapies. Am J Cancer Res. 2019;9:1536-45.
181. Bteich F, Di Bisceglie AM. Current and future systemic therapies for hepatocellular carcinoma. Gastroenterol hepatol. 2019;15:266-72.
182. Llovet JM, Ricci S, Mazzaferro V, et al; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-90
183. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018;391:1163-73.
184. Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018;379:54-63.
185. Bruix J, Qin S, Merle P, et al; RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;389:56-66
186. Zhu AX, Kang YK, Yen CJ, et al; REACH-2 study investigators. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20:282-96
187. Anugwom CM, Leventhal TM, Debes JD. Understanding immune perspectives and options for the use of checkpoint immunotherapy in HCC post liver transplant. Hepatoma Res. 2022;8:7.
188. Greten TF, Villanueva A, Korangy F, et al. Biomarkers for immunotherapy of hepatocellular carcinoma. Nat Rev Clin Oncol. 2023;20:780-98.
189. Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2022;23:77-90.
190. Zeng TM, Pan YF, Yuan ZG, Chen DS, Song YJ, Gao Y. Immune-related RNA signature predicts outcome of PD-1 inhibitor-combined GEMCIS therapy in advanced intrahepatic cholangiocarcinoma. Front Immunol. 2022;13:943066.
191. Sy, Ye YH, Zhou ZJ, Fan J, Zhou J, Zhou SL. Mutation-based therapies for intrahepatic cholangiocarcinoma: new options on the horizon. Hepatoma Res. 2024;10:3.
192. Serifis N, Tsilimigras DI, Cloonan DJ, Pawlik TM. Challenges and opportunities for treating intrahepatic cholangiocarcinoma. Hepat Med. 2021;13:93-104.
193. Wei P, Li Z. Advancing immunotherapy for intrahepatic cholangiocarcinoma: exploring the tumor immune microenvironment and innovative treatments. Hepatoma Res. 2024;10:39.
194. Vlerken-Ysla L, Tyurina YY, Kagan VE, Gabrilovich DI. Functional states of myeloid cells in cancer. Cancer Cell. 2023;41:490-504.
195. Cigliano A, Strain AJ, Cadamuro M. Signaling and molecular networks related to development and inflammation involved in CCA initiation and progression. Hepatoma Res. 2023;9:14.
196. Cadamuro M, Fabris L, Zhang X, Strazzabosco M. Tumor microenvironment and immunology of cholangiocarcinoma. Hepatoma Res. 2022;8:11.
197. Brivio S, Cadamuro M, Strazzabosco M, Fabris L. Tumor reactive stroma in cholangiocarcinoma: the fuel behind cancer aggressiveness. World J Hepatol. 2017;9:455-68.
198. Caligiuri A, Parola M, Marra F, Cannito S, Gentilini A. Cholangiocarcinoma tumor microenvironment highlighting fibrosis and matrix components. Hepatoma Res. 2023;9:30.
199. Gim G, Badri N. Challenges and opportunities for treating intrahepatic cholangiocarcinoma: targeted therapy. Hepatoma Res. 2023;9:51.
200. Cacoub P, Asselah T. Hepatitis B virus infection and extra-hepatic manifestations: a systemic disease. Am J Gastroenterol. 2022;117:253-63.
201. Asselah T, Loureiro D, Boyer N, Mansouri A. Targets and future direct-acting antiviral approaches to achieve hepatitis B virus cure. Lancet Gastroenterol Hepatol. 2019;4:883-92.
202. Nasser N, Tonnerre P, Mansouri A, Asselah T. Hepatitis-B virus: replication cycle, targets, and antiviral approaches. Curr Opin Virol. 2023;63:101360.
203. Wirth TC, Manns MP. The impact of the revolution in hepatitis C treatment on hepatocellular carcinoma. Ann Oncol. 2016;27:1467-74.
204. Poynard T, McHutchison J, Manns M, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122:1303-13.
205. Hu Z, Muroyama R, Kowatari N, Chang J, Omata M, Kato N. Characteristic mutations in hepatitis C virus core gene related to the occurrence of hepatocellular carcinoma. Cancer Sci. 2009;100:2465-8.
206. Lavery JA, Boutros PC, Knight D, Tammela T, Moskowitz CS, Jones LW. Association of exercise with pan-cancer incidence and overall survival. Cancer Cell. 2024;42:169-71.
207. Zhang Y, Cao C, Li C, et al. Physical exercise in liver diseases. Hepatology. 2024;Online ahead of print.
208. Chen X, Wu T, Xian L, et al. circGLS2 inhibits hepatocellular carcinoma recurrence via regulating hsa-miR-222-3p-PTEN-AKT signaling. Signal Transduct Target Ther. 2023;8:67.
209. Liu D, Liu W, Chen X, et al. circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis. Clin Transl Med. 2022;12:e662.
210. Cao G, Kuriyama S, Du P, et al. Complete regression of established murine hepatocellular carcinoma by in vivo tumor necrosis factor alpha gene transfer. Gastroenterology. 1997;112:501-10.
211. Cao G, Kuriyama S, Gao J, et al. Gene therapy for hepatocellular carcinoma based on tumour-selective suicide gene expression using the alpha-fetoprotein (AFP) enhancer and a housekeeping gene promoter. Eur J Cancer. 2001;37:140-7.
212. Yin J, Li N, Han Y, et al. Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31:3647-55.
213. Gheshlaghi A, Haghshenas MR, Safarpour AR, et al. IL-17 genetic variations increase the risk of cirrhotic/hepatocellular carcinoma in patients with hepatitis B virus infection. Iran J Immunol. 2021;18:130-40.
214. Yu L, Cheng Y ju, Cheng M liang, et al. Quantitative assessment of common genetic variations in HLA-DP with hepatitis B virus infection, clearance and hepatocellular carcinoma development. Sci Rep. 2015;5:14933.
215. Ma N, Zhang X, Yu F, et al. Role of IFN-ks, IFN-ks related genes and the DEPDC5 gene in hepatitis B virus-related liver disease. J Viral Hepat. 2014;21:e29-38.
216. Mangoud NOM, Ali SA, El Kassas M, Soror SH. Chitinase 3-like-1, Tolloid-like protein 1, and intergenic gene polymorphisms are predictors for hepatocellular carcinoma development after hepatitis C virus eradication by direct-acting antivirals. IUBMB Life. 2021;73:474-82.
